<tr>
	<td class="copyFragment" style="color: #4d4d4f; font-family: Arial, 'Helvetica Neue', Helvetica, sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: 400; line-height: 1.5; padding: 10px 0px 5px 0px;">
<b>Costa – NVAF Patients With Obesity (BMI ≥30) RWE<br>
<a href="https://www.tandfonline.com/doi/full/10.1080/03007995.2020.1762554" style="color: #401276; text-decoration: none">Effectiveness and safety of rivaroxaban versus warfarin in obese NVAF patients</a></b><br>
<span style="font-size: 12px; font-style: normal;">*Results are not intended for direct comparison with clinical trials.</span>
</td>
</tr>
<tr><td style="border-bottom: 3px solid #4d4a4b;"></td><tr></tr>